{"id":7816,"date":"2021-04-11T22:52:18","date_gmt":"2021-04-11T22:52:18","guid":{"rendered":"https:\/\/sooha.org\/en\/?p=7816"},"modified":"2021-04-13T05:56:59","modified_gmt":"2021-04-13T05:56:59","slug":"somalia-to-receive-200k-doses-of-sinopharm-vaccine","status":"publish","type":"post","link":"https:\/\/sooha.org\/en\/2021\/04\/11\/somalia-to-receive-200k-doses-of-sinopharm-vaccine\/","title":{"rendered":"Somalia to receive 200K doses of Sinopharm vaccine"},"content":{"rendered":"

MOGADISHU —<\/strong> Somali state media said that the federal government expects a shipment of Chinese-made COVID-19 vaccines to arrive in the capital on Sunday.<\/p>\n

Somalia announced that it had inked a deal with Chinese vaccine maker Sinopharm to obtain 200,000 doses of the BBIBP-CorV COVID-19 vaccine on Wednesday as critics globally raise questions about the vaccine efficacy of Chinese-made vaccines.<\/p>\n

Somalia’s ambassador to China, Awale Kulane, signed the agreement with his deputy head of mission, Said Mire. Kulane said that he hoped more deliveries would follow.<\/p>\n

The decision to import the vaccines comes as questions about the effectiveness of Chinese vaccines compared to others on the market.<\/p>\n

China has produced four vaccines that have efficacy rates that trail behind Western rivals.<\/p>\n

China’s Sinovac reported that Brazil’s trials resulted in about 50% efficacy in preventing infection and 80% in preventing hospitalization or serious medical attention. Sinopharm’s two vaccines fared better with an efficacy rate of 79.3 and 72.5, respectively. CanSino’s vaccine reported a 65.2% efficacy.<\/p>\n

Also, there are reports that a third dose is required for ample protection, and the Chinese-produced vaccines have come under intense scrutiny for not making full disclosure on their phase 3 trials.<\/p>\n

Pfizer-BioNTech and Moderna have boasted efficacy rates of 95% and 94%.<\/p>\n

The efficacy rate is the percentage reduction of COVID19 in a vaccinated group compared to the unvaccinated.<\/p>\n

The vaccine has been authorized for use in over 30 countries and has strong demand from developing countries as vaccine shortages begin to bite.<\/p>\n

Despite supplying over 100 million doses globally, the vaccine is not inspiring unwavering confidence. A recent study revealed that only 40% of Hong Kong residents said they were willing to take the Sinopharm vaccine.<\/p>\n

The World Health Organization’s Strategic Advisory Group of Experts (SAGE) said that it hoped to issue recommendations on the Chinese-made vaccines by the end of April. If approved, the vaccines will be used under the global vaccine-sharing program, COVAX.<\/p>\n

Somalia received its first shipment of vaccines in mid-March when it received 300,000 doses of the Oxford-Astrazenea vaccine from the COVAX initiative.<\/p>\n

Somalia has recorded 12,271 cases of COVID-19 and 605 death since the onset of the pandemic, but limited testing means that there are legitimate fears that the actual number could be much higher.<\/p>\n

Source: HOL\u00a0 \u00a0 \u00a0 \u00a0Origin: View original<\/span><\/a><\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

MOGADISHU — Somali state media said that the federal government expects a shipment of Chinese-made COVID-19 vaccines to arrive in the capital on Sunday. Somalia announced that it had inked a deal with Chinese vaccine maker Sinopharm to obtain 200,000 doses of the BBIBP-CorV COVID-19 vaccine on Wednesday as critics globally raise questions about the …<\/p>\n","protected":false},"author":1,"featured_media":7814,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,1],"tags":[],"class_list":["post-7816","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-health-cluster","category-news"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/posts\/7816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/comments?post=7816"}],"version-history":[{"count":2,"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/posts\/7816\/revisions"}],"predecessor-version":[{"id":7819,"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/posts\/7816\/revisions\/7819"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/media\/7814"}],"wp:attachment":[{"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/media?parent=7816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/categories?post=7816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sooha.org\/en\/wp-json\/wp\/v2\/tags?post=7816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}